The SMARCB1 gene (INI1, BAF47) is a member of the SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin remodeling complex, involved in the epigenetic regulation of gene transcription. SMARCB1 acts as a tumor suppressor gene, and loss of function of both alleles gives rise to SMARCB1-deficient tumors. The prototypical SMARCB1-deficient tumor is the malignant rhabdoid tumor (MRT) which was first described in the kidney but also occurs in soft tissue, viscera, and the brain (where it is referred to as atypical teratoid rhabdoid tumor or AT/RT). These are overwhelmingly tumors of the very young, and most follow an aggressive and ultimately lethal course. Morphologically, most but not all contain a population of ''rhabdoid'' cells, which are large cells with abundant cytoplasm, perinuclear spherical inclusions, and eccentric vesicular nuclei with large inclusion-like nucleoli. MRT immunohistochemistry reveals complete loss of SMARCB1 nuclear expression, and molecular analysis confirms biallelic SMARCB1 inactivation in the vast majority. Rare AT/RTs have loss of SMARCA4, another SWI/SNF member, rather than SMARCB1. With the widespread adoption of SMARCB1 immunohistochemistry, an increasing number of SMARCB1-deficient tumors outside of the MRT-AT/RT spectrum have been described. In addition to MRT and AT/RT, pediatric tumors with complete loss of SMARCB1 expression include cribriform neuroepithelial tumor, renal medullary carcinoma, and epithelioid sarcoma. Tumors with variable loss of SMARCB1 expression include subsets of epithelioid malignant peripheral nerve sheath tumor, schwannomas arising in schwannomatosis, subsets of chordomas, myoepithelial carcinomas, and sinonasal carcinomas. Variable and reduced expression of SMARCB1 is characteristic of synovial sarcoma. In this review, the historical background, clinical characteristics, morphology, immunohistochemical features, and molecular genetics most germane to these tumors are summarized. In addition, familial occurrence of these tumors (the rhabdoid tumor predisposition syndrome) is discussed. It is hoped that this review may provide practical guidance to pathologists encountering tumors that have altered expression of SMARCB1.
Introduction
Rhabdoid tumors have been a source of speculation and controversy since their first description in 1978. Even the designation of ''rhabdoid tumor'' reflected their uncertain place in the wide spectrum of pediatric malignancies, the sobriquet based upon a superficial morphologic resemblance to rhabdomyosarcoma, an unrelated tumor characterized by true myogenesis and differing from the ''rhabdoid tumor'' genetically, clinically, and despite the name, even in most morphologic respects. Classic rhabdoid tumors have arresting features by light microscopy: large vesicular nuclei with huge inclusion-like nucleoli, copious eosinophilic cytoplasm, and peculiar spherical cytoplasmic inclusions which reminded early observers of differentiating rhabdomyoblasts, prompting the appellation of ''rhabdoid,'' soon entrenched in the literature. Morphologically unique, these tumors bore a grim clinical signature: affliction of the very young, rapid aggressive growth, predilection for certain areas of the body, and a nearly universal lethal outcome.
In the last 4 decades, these tumors have been the focus of light microscopic, ultrastructural, and immunohistochemical analyses by many astute pathologists, striving to better diagnose and classify these tumors. As with other rare pediatric neoplasms, recognition of rhabdoid tumors was facilitated by cooperative group studies involving organized collection and study of tumors from a wide network of institutions. The National Wilms Tumor Study (NWTS), established in 1969 under the leadership of radiation oncologist Dr Giulio D'Angio, was one of the earliest of these group studies. Although the focus was on Wilms tumor, all types of pediatric renal tumors were evaluated. Dr Bruce Beckwith, the founding NTWS pathologist, is credited (with colleague Nigel Palmer) with first recognizing the classic features of rhabdoid tumor of the kidney. In a landmark 1978 paper linking prognosis of Wilms tumor to histologic features, he described 8 tumors (out of 427 studied) that had a ''rhabdomyosarcomatous'' pattern and a poor prognosis, seemingly quite different from other Wilms tumors. 1 These tumors were composed of polygonal cells with abundant cytoplasm, vesicular nuclei with very prominent nucleoli, and rounded cytoplasmic hyaline inclusions; all features we now associate with classic rhabdoid tumor.
Although light microscopy suggested rhabdomyoblastic differentiation, electron microscopy and immunohistochemistry pointed in a different direction. In their 1981 ultrastructural study of 11 rhabdomyosarcomatoid variants, Haas et al. described concentric arrays of cytoplasmic filaments within the cytoplasm and no convincing evidence of rhabdomyoblastic differentiation. In their words: ''because of the light microscopic features suggesting rhabdomyosarcoma and in the interest of avoiding an unjustified appellation of sarcoma or carcinoma, we now refer to the tumor as malignant 'rhabdoid tumor' of the kidney.'' 2 Also in 1981, Palmer and Beckwith noted an association between renal rhabdoid tumors and coexisting intracranial masses, most of which at that time were diagnosed as medulloblastomas. 3 This observation suggested a constitutional genetic abnormality in some of these children and laid the groundwork for the later elucidation of the rhabdoid tumor predisposition syndrome (RTPS).
Eleven years after the initial description of renal rhabdoid tumor, Weeks et al. published a comprehensive study of 111 cases from the National Wilms Tumor Study. 4 This study confirmed the young patient age at presentation, the poor prognosis of these tumors, and resistance to Wilms focused chemotherapy. In addition, the authors described varied morphologic patterns (to be described later in this review) and confirmed the lack of true rhabdomyoblastic differentiation in rhabdoid tumors.
Numerous case reports and small series subsequently emerged of tumors with rhabdoid cells arising outside of the kidney. As cases of similar tumors outside of the kidney (extrarenal rhabdoid tumor) accumulated, so did descriptions of novel morphologic patterns, variant immunohistochemical profiles, and clinical behaviors. Some of the tumors occurred in older patients, and others seemed to follow a less aggressive course. Indeed, once pathologists first started focusing attention on rhabdoid cells, it became apparent that such cells were occasionally present in other tumor types. This fueled controversy over the nosology of these tumors, their biologic origin, and even whether they were unique entities in themselves, or simply extreme morphologic variations of other tumors. The latter opinion was bolstered by the finding of rhabdoid cells in a wide range of ''parent neoplasms,'' including a variety of carcinomas, sarcomas, and melanomas. The term ''composite extrarenal rhabdoid tumor'' was developed to account for these tumors. 5 Extrarenal tumors composed of rhabdoid cells that could not be placed convincingly into other known entities were provisionally described as ''poorly differentiated neoplasm with rhabdoid features.'' 6 NWTS pathologists were aware of this and published a series of 56 renal tumors (Wilms tumors, mesoblastic nephroma, various renal carcinomas, oncocytoma, lymphoma, and rhabdomyosarcoma) that harbored rhabdoid-like cells. 7 Nosologic uncertainty also prevailed in neuropathology, with some observers considering tumors with rhabdoid cells to simply be an unusual morphologic variation of medulloblastoma/primitive neuroectodermal tumor (PNET). Compelling evidence to the contrary came in 1995 when Rorke et al. defined the features of central nervous system (CNS) rhabdoid-like tumors and conclusively established them as a genetically, clinically, and immunohistochemically distinct entity. 8 Although in many respects similar to the rhabdoid tumor of the kidney, a small subset of these tumors displayed histologic or immunohistochemical features of divergent mesenchymal or epithelial differentiation, which prompted the appellation of ''atypical teratoid/ rhabdoid tumor'' or AT/RT. Rorke, Biegel, and colleagues emphasized that AT/RTs differed from medulloblastomas because of their polyphenotypic immunoprofiles (positivity for epithelial membrane antigen [EMA], vimentin, and smooth muscle actin) and consistent chromosome 22 abnormalities. 9 Two years later, Versteege et al. mapped the 22q11.2 locus disrupted in a series of rhabdoid tumor cell lines to the hSNF5/INI1 locus (now known as SMARCB1) and firmly established that these tumors were a distinct biologic entity. 10 Almost concurrently, groups led by Sevenet and Biegel identified patients with constitutional mutations of SMARCB1, and a predisposition to development of rhabdoid tumors in multiple sites, as well as other tumors, and thus began to explore the genetics of RTPS. 11, 12 In 2004, Judkins and colleagues established that immunohistochemistry for the SMARCB1 (INI1) protein was a sensitive and fairly specific tool for diagnosing rhabdoid tumors, regardless of whether they were renal, extrarenal, or within the CNS. 13, 14 Adoption of SMARCB1 immunohistochemistry to clinical practice was rapid, and as more tumors were stained, it became clear that while the sensitivity remained robust, a number of other tumors also manifested either absent or weak staining for SMARCB1. Some of these tumors seemed closely related to rhabdoid tumors, whereas others were markedly different in appearance and behavior. Although rhabdoid tumors almost uniformly harbored mutations or deletions of the SMARCB1 gene, this was not necessarily the case with some of the other tumors that showed complete or partial loss of SMARCB1 immunostaining. Advances in molecular understanding, discussed in detail in the following sections, have helped to resolve this discrepancy.
As SMARCB1 immunohistochemistry is now a cornerstone of rhabdoid tumor diagnosis, it is essential for the diagnostic pathologist to have an understanding of the wide spectrum of childhood SMARCB1-deficient tumors (Table 1) and to be able to distinguish between them, as there are significant differences in clinical behavior and treatment. This article is a review of the clinical, histologic, and immunohistochemical characteristics of pediatric SMARCB1-deficient tumors, focusing on points of differential diagnosis that may assist in arriving at a correct diagnosis, with emphasis placed on the molecular genetic features most diagnostically useful.
The SMARCB1 Gene and SWF/SNF Complex
This gene has been known by a variety of names, including INI-1 (integrase inactivator 1) and BAF47 (BRM or BRG1 associated factors subunit of 47 kDa). The terminology used here is the Human Genome Organization designation of SMARCB1, which is a conglomeration of the rather intimidating full gene name ''(mating-type switching)/SNF-related matrix-associated actin-dependent regulator of chromatin, subfamily B, member 1.''
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SMARCB1 is a core subunit of the SWI/sucrose nonfermenting ATP-dependent chromatin remodeling complex (SWI/SNF). This complex is composed of an ATPase-dependent gene BRM(SMARCA2) or BRG1 (SMARCC2), as well as 3 main subunits (1 of which is SMARCB1), and a variable number of accessory subunits ( Figure 1 ). 21 SWI/SNF plays a key role in the activation and repression of gene transcription through chromatin remodeling, regulating gene transcription by dissociation, sliding, or replacement of nucleosomes. The role of SMARCB1 within the complex is not completely understood, but it has features of an epigenetic tumor suppressor gene. It also downregulates cell proliferation by interacting with cell cycle genes such as p16, pRb, and HDAC1.
The SMARCB1 protein is encoded by 9 exons at 22q11.23 and is universally expressed in all normal mammalian nucleated cells. Loss of expression reflects biallelic inactivation resulting from SMARCB1 gene locus mutations or deletions. These biallelic events may occur with or without a predisposing germline mutation. 22 Nonsense and frameshift mutations usually result in the absence of SMARCB1 expression, whereas missense, in-frame deletions, and splice-site mutations result in altered SMARCB1 protein expression. 23 
Tumors With Complete Loss of SMARCB1 Expression Malignant Rhabdoid Tumor
Extracranial malignant rhabdoid tumor (MRT) is the quintessential SMARCB1-deficient tumor, and although first described in the kidney, it has since been reported in nearly all parts of the body, including soft tissue and viscera. As the pathologic features of renal and extrarenal MRT are identical, they will both be referred to in this review simply as MRT. MRT mainly occurs in children less than 3 years of age, although occasionally older patients are afflicted. A highly aggressive tumor capable of metastasizing widely, 3-year event-free survival rates have ranged from 31% to 38%, and 5-year overall survival rates have ranged from 15% to 36% (Figure 2 ). 24, 25 There is as yet no established standard treatment, which may be related to the small number of cases, and the historical stratification of these tumors depends upon the site of origin (renal, extrarenal, and CNS). 26 Young age at diagnosis has so far been the only consistent adverse prognostic factor. 26 Congenital examples with widespread dissemination and a rapidly progressive course have been reported. 27, 28 Interestingly, congenital dermal ''neurovascular hamartomas,'' composed of a proliferation of capillaries in a background of bland spindle cells with possible neural features have been associated with MRT development in infants. 29 Most rhabdoid tumors are composed of patternless sheets of discohesive polygonal cells, with varying degrees of background necrosis (Figure 3) . Occasionally, the tumors can have a nested pattern imparted by fibrous septae, and with central discohesion, the picture can be reminiscent of alveolar rhabdomyosarcoma (Figure 4 ). Other tumors may be more sclerotic, and some are composed of cells dispersed in a myxohyaline ground substance. 30 This appearance can mimic chordoma. Heterologous elements are unusual. Cytologically, a key feature is the ''rhabdoid'' cell, which is large and epithelioid, with an eccentrically placed vesicular nucleus which Figure 5 ). Because of this, lack of classic ''rhabdoid'' cells within an undifferentiated tumor does not exclude the possibility of MRT, especially in small biopsy samples. 31 Most MRTs are composed of polygonal cells; however, some may display mild spindling.
Although the diagnosis of MRT can be strongly suspected in many cases based on hematoxylin and eosin morphology, confirmatory immunohistochemistry is necessary in nearly all cases, and as mentioned earlier in this review, SMARCB1 (INI1) is the most critical stain in the diagnostic workup. MRTs display total lack of nuclear SMARCB1 staining. As SMARCB1 is normally expressed in all mammalian nucleated cells, intratumoral inflammatory and vascular endothelial cells serve as ready internal controls ( Figure 6 ). 13 Furthermore, most MRTs also display a polyphenotypic immunoprofile, with the expression of neural, mesenchymal, and epithelial markers. Nearly all express vimentin, and the majority express EMA and/or broad spectrum cytokeratins. There may be variable expression of neuron-specific enolase (NSE), synaptophysin, glial fibrillary acidic protein (GFAP), and smooth muscle actin. Desmin and CD34 are rarely expressed. As a potential source of confusion with Ewing sarcoma, over half of MRTs display perimembranous CD99 staining.
Tumors with SMARCB1 nuclear retention in the face of either focal or diffuse rhabdoid cytology fall under the rubric of ''composite'' rhabdoid tumors, the rare exceptions being tumors with deficiency of other SWF/SNF complex components, discussed later in this review.
Focal rhabdoid morphology can be seen in carcinomas, sarcomas, melanomas, and glial or meningeal tumors. 32 In fact, most so-called composite rhabdoid tumors can be placed into other diagnostic categories after judicious application of immunohistochemistry and molecular diagnostics. 33 In these cases, the rhabdoid morphology may be the morphologic culmination of a progression of anaplastic changes unrelated to primary SMARCB1 loss, possibly heralding a more aggressive clinical behavior. 34 Electron microscopy of histologically classic rhabdoid cells reveals prominent cytoplasmic whorls of intermediate filaments and large nucleoli ( Figure 7 ). 35 Features of skeletal muscle, epithelial or peripheral nerve sheath differentiation are not present. Most MRT ultrastructural studies were performed prior to the elucidation of the role of SMARCB1 in MRT, and thus many of the early case series were composed of a mixture of true MRTs and composite MRTs (other tumor entities with rhabdoid cells). There are no specific ultrastructural features pathognomonic for a SMARCB1 mutated/ deleted MRT.
Although the diagnosis of MRT can be established in many cases by light microscopy and immunohistochemistry, molecular genetic investigation is a recommended part of the diagnostic workup. One reason is that the molecular mechanisms underlying SMARCB1 loss differ from entity to entity, as summarized in Table 1 , and another is that other tumors (discussed later) may also show lack of SMARCB1 staining. Finally, the diagnosis of MRT should always prompt consideration of molecular testing for the RTPS.
As compared to most other malignancies, and perhaps surprisingly, considering the highly aggressive nature of MRT, these tumors have a rather simple genome with an extremely low rate of recurring mutations, other than SMARCB1 inactivation. 36 The overwhelming majority of MRTs display biallelic SMARCB1 inactivation resulting in complete loss of expression, 21 with the rare exceptions appearing to be those with loss of SMARCA4. Underlying causative mutations include whole gene deletions, large and small intragenic deletions/insertions/ duplications, and nonsense and splice-site mutations, with missense mutations rarely seen. 21 Interestingly, the type of genetic event causing SMARCB1 loss varies by the site of tumor origin. The majority of MRTs outside of the CNS display homozygous SMARCB1 deletions, whereas only a third of CNS AT/RTs do. 37 Moreover, extrarenal MRTs appear more likely to have smaller deletions involving the SMARCB1 locus, usually due to unbalanced translocations, than renal MRTs, which tend to have complex deletion/duplication patterns. 37 
MRT of the Liver
MRT arising within the liver of a young child may prompt consideration of the alternative diagnosis of the small cell undifferentiated (SCU) variant of hepatoblastoma ( Figure 8 ). The SCU variant is characterized by the sheets of small undifferentiated cells, 5 to 10 lm in diameter, with minimal cytoplasm, fine chromatin, nonprominent nucleoli, and variable SMARCB1 staining. Mitotic activity can also be variable. 38 The small cell histology may account for a small portion of an otherwise typical hepatoblastoma, or it may be the only pattern present, and its presence had been associated with a significantly poorer outcome than for hepatoblastomas in general. Recently, some of these tumors were noted to have loss of SMARCB1 expression, 39 raising the possibility that some were indeed hepatic MRTs and not hepatoblastomas. In a recent Children's Oncology Group study, SCU pattern tumors with immunohistochemical retention of SMARCB1 had a significantly better outcome (6 out of 7 patients are alive after the mean follow-up of 5.4 years) than tumors in which SMARCB1 was lost. 40 Also in a recent review of SCU hepatoblastomas with the absence of SMARCB1 expression from the Kiel Pediatric Tumor Registry, 19 out of 19 cases analyzed by either fluorescence in situ hybridization (FISH) or multiplex ligation-dependent probe amplification showed deletions involving the SMARCB1 gene. 41 Overall, there is burgeoning evidence to suggest that (1) when SMARCB1 is retained, SCU hepatoblastoma loses its adverse prognostic significance and (2) SCU hepatoblastomas with loss of SMARCB1 are truly MRTs of the liver. 40, 41 Atypical Teratoid/Rhabdoid Tumor By convention, rhabdoid tumors of the brain are referred to as AT/RTs, reflecting an early perception that these tumors are more likely to harbor areas of mesenchymal differentiation and even epithelial ''teratoid'' foci. AT/RTs are rare, representing less than 2% of pediatric brain tumors, and are found in roughly equal proportions above and below the tentorium, with 7% occurring within the spinal cord. 23, 42 Like MRTs they occur in young patients, with a median age of 1.4 years, and are very rare in children over 10 years. Overall survival is very poor, and in the largest series to date, the median survival after diagnosis was just 9 months. 42 Nearly all AT/RTs, like their soft tissue MRT counterparts, demonstrate loss of nuclear SMARCB1 staining; very rarely SMARCA4 (BRG1), another component of the SWF/SNF complex is lost instead (see later). The histologic features of AT/RT are in general similar to those of MRT; in fact all of the histologic features described earlier for MRT also apply to AT/RT ( Figure 9 ). In the brain, choroid plexus carcinoma may have similar histologic features to AT/RT; however, SMARCB1 and SMARCA4 immunohistochemical staining can reliably distinguish between the two. 43 Given the very close similarity of MRT and AT/RT, the two may represent the same entity occurring in different anatomic locations. Both neoplasms may be largely or completely composed of undifferentiated medium-sized cells bereft of classical rhabdoid features, which in the CNS would prompt consideration of either PNET or medulloblastoma and in soft tissues an atypical Ewing or undifferentiated sarcoma. AT/RTs often have primitive small to medium vesicular nuclei and vacuolated cytoplasm. Although small round blue cell areas may be encountered, they are usually not numerous. 44 As undifferentiated nonrhabdoid histology is relatively common in CNS tumors, performing SMARCB1 immunohistochemistry before diagnosing a medulloblastoma or PNET may be prudent. 44 Although the finding of spindle cell areas, as well as true teratoid areas composed of organized epithelial structures has been emphasized in the earlier neuropathology literature, more recent studies performed on SMARCB1 nonretained CNS tumors have found that these areas are rare, 44 bringing into question the continued use of the adjective ''teratoid'' for these neoplasms.
The immunohistochemical profile of AT/RT is also similar to MRT outside of the CNS, with both commonly showing immunohistochemical evidence of epithelial and/or mesenchymal differentiation. In addition to SMARCB1 loss, AT/RT commonly shows polyphenotypic staining for vimentin, broad spectrum cytokeratins, and EMA. Emphasized in the neuropathology literature is that combined expression of EMA and smooth muscle actin is relatively specific for ATRT. 45 Also frequently expressed are GFAP, neurofilament protein, synaptophysin, and CD99. 45 Approximately 40% of AT/RTs (and MRT) express claudin-6. 17 There is tentative evidence, as yet unconfirmed, that a lack of cell membranous claudin-6 expression in AT/RT may be associated with a more favorable prognosis. 
Cribriform Neuroepithelial Tumor
Very recently described, the cribriform neuroepithelial tumor (CRINET) is an unusual CNS tumor that lacks SMARCB1 expression, yet has a favorable prognosis and lacks histologic rhabdoid features. 46 First described as arising in the vicinities of the third and fourth ventricles, later examples have arisen from the lateral ventricle and medulla. Of the handful of cases reported to date, all have occurred in young children and relapses after treatment have been rare (median age at diagnosis of 18 months, with the oldest child aged 11 years). Histologically, the tumors have biphasic architecture characterized by cribriform to trabecular strands of small undifferentiated cells, admixed with more solid cellular sheet-like areas of compact growth (Figure 10 ). True rosettes may be present. Tumor nuclei have dense chromatin and lack prominent nucleoli, and cytoplasmic inclusions are absent. Tumor necrosis may be present, and mitotic activity ranges up to 3 per high-power field (HPF).
In addition to having loss of nuclear SMARCB1 expression, immunohistochemistry reveals positive staining for EMA, vimentin, and synaptophysin. Pancytokeratin, low-molecular-weight cytokeratin, and S100 staining may be present; however, GFAP, neurofilaments, neuronal nuclear antigen, NSE, and chromogranin have all been reported as negative. 46 The histologic differential diagnosis includes AT/RT, choroid plexus carcinoma, PNET, medulloepithelioma, and ependymoblastoma. Unlike AT/RT, CRINETs do not have rhabdoid features of cytoplasmic inclusions and prominent nucleoli. Moreover, AT/RTs tend to have less prominent epithelial differentiation and cribriforming. 47 Choroid plexus carcinomas should express nuclear SMARCB1 and although some early reports suggested the contrary, cases initially described as SMARCB1-deficient choroid plexus carcinomas were most likely AT/RTs. 43, 46 Moreover, unlike choroid plexus carcinoma, immunohistochemistry for potassium channel Kir7.1 is negative in CRINETs. PNET, medulloepithelioma, and ependymoblastoma can be ruled out by demonstrating retention of SMARCB1 nuclear reactivity.
Molecular studies of CRINET are limited, given the very recent recognition and rarity of this tumor. SMARCB1 partial exon duplications, deletions, and point mutations have been described. 47, 48 Moreover, cases have arisen in a family in the setting of a germline SMARCB1 mutation, suggesting a heritable tumor syndrome similar to the RTPS. 49 
Renal Medullary Carcinoma
Renal medullary carcinoma (RMC) is a rare and extremely aggressive tumor that almost exclusively arises in patients with sickle cell hemoglobinopathy, usually sickle-cell trait. 50 Why it occurs in this setting has never been clearly established, although hypoxia-related sickling may play a role. Unlike renal cell carcinoma which is usually cortically based, RMC arises from the renal pelvic calyceal/renal papillae region, an area subject to low oxygen pressures and an acid environment. 51 Hypoxia-induced vascular endothelial growth factor and hypoxia-inducible factor expression may then lead to tumor initiation. 52 The tumor usually arises in young adulthood or adolescence, and in children, it is more common in males than females. 53 Of the several hundred cases reported to date, 88% occurred in patients with sickle-cell trait, and 8% in patients with sickle cell disease. 51 Approximately half of cases have occurred in children, and the mortality rate is a sobering 95%. 51 At diagnosis, the tumor may be large, often hemorrhagic and necrotic, ranging from 1.9 to 18 cm, and for mysterious reasons appears to more commonly arise in the right kidney than in the left (Figure 11) . 53 Lymph node metastases are often present at diagnosis. 50 The histologic appearance of RMC is high grade and architecturally variable, with growth patterns ranging from yolk sac tumor-like, to reticular, cribriform, adenoid, and solid ( Figure 12 ). Sickled erythrocytes can often be seen, and desmoplasia may be prominent. Most tumors demonstrate at least focal rhabdoid features, with eccentrically placed nuclei, prominent nucleoli, and prominent eosinophilic cytoplasm. In addition to loss of SMARCB1 staining, immunohistochemistry shows positivity for AE1/AE3, CK7, CAM5.2, EMA, and vimentin. 53, 54 Approximately 70% show nuclear OCT3/4 staining, which can cause diagnostic confusion with yolk sac tumor. 55 Molecular analyses of RMCs have shown loss of heterozygosity or hemizygous deletions for SMARCB1 in the majority of these tumors. 53, 16 Several other tumors may present difficulties in differential diagnosis, including MRT, vinculin-anaplastic lymphoma kinase (VCL-ALK) translocation renal cell carcinoma, and collecting duct carcinoma. MRT can be morphologically and immunohistochemically indistinguishable from RMC. The clinical setting is usually different however, as MRT most commonly occurs in children under 3 years, whereas it would be very unusual to encounter RMC in a child less than 5 years. A history of sickle cell hemoglobinopathy (or the finding of sickle cells on histologic examination) would also direct the diagnosis toward RMC. VCL-ALK renal cell carcinoma is a newly described entity, and the few cases reported to date have all occurred in patients with sickle-cell trait; a similar demographic to RMC patients. 56 Moreover, the histology of VCL-ALK renal cell carcinoma may overlap with RMC as both can contain polygonal tumor cells, vesicular nuclei, and prominent eosinophilic cytoplasm. Unlike MRT, however, VCL-ALK renal cell carcinoma does not demonstrate loss of SMARCB1. Although renal collecting duct carcinoma generally shows immunohistochemical retention of SMARCB1, rare cases have been SMARCB1 weak or negative, prompting speculation that renal collecting duct carcinoma and RMC are part of a clinicopathologic spectrum. 57 Since collecting duct carcinomas are seen in middle aged to older adults, it is reasonable that high-grade adenocarcinomas with loss of SMARCB1 expression arising in pediatric patients with sickle cell hemoglobinopathy would best be classified as RMC and not collecting duct carcinoma.
Epithelioid Sarcoma
Epithelioid sarcomas (ES) can occur as ''classic'' or ''proximal-type'' tumors. Primarily seen in adolescents and young adults, with a 2:1 male predilection, these are rare malignancies, accounting for less than 8% of pediatric nonrhabdomyosarcomatous sarcomas. 58 Classic ES most commonly occurs in the distal extremities (upper > lower) but may be seen in other locations. It is typically indolent in growth but with a distressingly high (over 90%) propensity for multiple recurrences and an overall unfavorable prognosis due to the late occurrence of distal metastases. Metastases can occur many years after presentation, usually to regional lymph nodes, distant skin, and lung. 58 Initially, ES clinically is often mistaken for a benign condition, as it is often superficial in location and may be quite small, mimicking a benign neoplasm, chronic ulcer, infection, a reactive process, or even a foreign body. It may occur as either a single or a multifocal lesion at diagnosis.
Histologic diagnosis may be difficult as well, and although solid figures are hard to come by, it seems that classic ES would rank highly among malignancies initially mistaken under the microscope for a benign condition. Classic ES often presents a nodular architecture with central or geographic necrobiosis, simulating a granulomatous process, such as granuloma annulare or rheumatoid nodule ( Figure 13 ). Intratumoral hemorrhage can lead to an angiomatoid appearance and focal calcification may be seen. 58 The borders of the lesion are often ill-defined but may be well-marginated. Classic ES tumor cells are plump, spindled to epithelioid, and may appear deceptively bland, with little in the way of pleomorphism and variable, often low mitotic activity. Rhabdoid inclusions may be present, and tumor nuclei tend to be enlarged and centrally located, with variably prominent nucleoli. The presence of an infiltrative architecture and atypical cytologic features of spindled or epithelioid cells in subcutaneous or deep granulomatous lesions should raise suspicion for ES and prompt further immunohistochemical workup. Both classic and proximal-type ES cells have a unique bi-immunophenotypic signature, coexpressing vimentin and broad spectrum cytokeratins as well as EMA. Cytokeratin positivity is particularly useful in distinguishing classic ES from granulomatous conditions. Approximately half also express CD34, which is useful to distinguish them from carcinomas and MRT. Up to 90% of ES as defined by these histologic features and biphenotypic immunohistochemistry also demonstrate loss of SMARCB1 nuclear staining. ETS-related gene (ERG) and glucose transporter-1 (GLUT-1) staining have been described in approximately 40% of cases. 58 Desmin, S100, and FLI-1 are generally negative.
Proximal-type ES was first described in 1997 by Guillou et al. 59 Like classic ES, the proximal-type variant is most common in young adults but can occur over a wide age range. Proximal-type ES occurs most commonly in the perineal/pelvic/genital regions and proximal limb girdles. Unlike classic ES, these tumors are usually deep seated and are often large, with tumors up to 20 cm in size reported. 59 The proximal type is more aggressive than the classic type, metastasizing earlier, and with an overall survival rate of 35% in one series. 60 Histologically, proximal-type ES lacks the pseudogranulomatous pattern of classic ES and is composed of sheets of large, cytologically atypical epithelioid cells, with more pleomorphism than seen in classic ES (Figure 14) . These cells frequently have rhabdoid features. Osteoclast-like giant cells may be present. 61 Some tumors display mixed features of both classic and proximal-type tumors. 58 Immunohistochemically, proximal-type ES is similar to classic ES. A difficult area of differential diagnosis is between proximal-type ES and MRT, as the 2 entities share morphologic and immunohistochemical features. In general, such a tumor would be diagnosed as an MRT if it occurred in a child under the age of 5 or so, and would be diagnosed as a proximal-type ES if it occurred in an adolescent or young adult. CD34, if positive, would militate toward a diagnosis of ES, as CD34 is usually negative in MRT; however, only about half of ES will express CD34. At present, proper diagnostic assignment of a CD34-negative tumor with features of MRT/ proximal ES in the older child appears somewhat arbitrary. Although several recent studies have evaluated other immunohistochemical stains (glypican 3, ERG, and sal-like protein 4 [SALL4]) to address this issue, further work is necessary to follow-up and expand upon them. In one study, ERG was negative in all cases of MRT and positive in 25% of proximal-type ES, and SALL4 positive in two-thirds of MRT but only rarely in ES. 62 In another study, glypican 3 staining was overexpressed in over 40% of MRT but negative in nearly all ES. 63 The SMARCB1 protein loss in both classic and proximal-type ES stems from deletions of the region of 22q11 encoding the SMARCB1 gene, which are homozygous in the majority (83%-90%) of cases. 19, 64 Through sequencing studies, it appears that the rate of SMARCB1 mutations and intragenic deletions is very low. 64 Interestingly, it is now clear that even classic ES can occur in the background of a germline SMARCB1 mutation. 19 Given these findings, it has been suggested that classic and proximaltype ES be considered as a single pathologic entity, regardless of the site of presentation. 19 Moreover, the molecular genetic similarities between MRT and ES raise questions as to whether ES should remain a distinct diagnostic category from MRT.
Tumors With Variable Loss of SMARCB1 Expression

Peripheral Nerve Sheath Tumors: Epithelioid Malignant Peripheral Nerve Sheath Tumor and Schwannomatosis
Epithelioid malignant peripheral nerve sheath tumor (EMPNST) is a rare form of MPNST that predominantly occurs in adults and occasionally in children, as young as 6 years of age. It differs from conventional MPNST in 4 major aspects: (1) some cases arise from preexisting schwannomas whereas other MPNSTs rarely if ever do, (2) it has no convincing association with neurofibromatosis, (3) it displays strong and diffuse staining with S100, and (4) most germane to this review, many tumors have loss of SMARCB1 by immunohistochemistry. 65 Clinically, EMPNST can occasionally metastasize and have a fatal outcome, although with the limited data available, the overall prognosis appears more favorable than conventional MPNST. 65 Many sites can be involved, with nearly half of these tumors arising in the lower extremities. Tumor sizes have ranged from 0.4 to 20 cm, and most occur superficially in the dermis or subcutis, with rare examples arising viscerally or in deep soft tissue. In a recent comprehensive series, 14% arose from a preexisting schwannoma. 65 Histologically, these tumors are composed of a population of fairly uniform but moderately to severely atypical epithelioid cells (Figure 15 Immunohistochemistry reveals strong, uniform S100 positivity. Over half of the cases express GFAP and rare cases express EMA, but not cytokeratin. Melanocytic markers Melan-A and HNB45 are negative. 65 Unlike most other sporadic and NF1-associated MPNST, EMPNST has retained H3K27me3 staining, reinforcing that these tumors are distinct entities from other forms of MPNST. 66, 67 Loss of SMARCB1 via immunohistochemistry may be seen in a significant percentage of cases, ranging from a quarter to two-thirds. The genetic events underlying this loss are not well understood, but may be related to loss of material on chromosome 22q11.3 encoding the SMARCB1 locus, in proximity to the NF2 gene encoded on 22q12. 68 The differential diagnosis with epithelioid schwannoma can be challenging, as both show strong S100 positivity. In general, epithelioid schwannomas should display less nuclear atypia, lack atypical mitoses, and lack necrosis. Melanoma may histologically resemble EMPNST, but expresses melanoma-associated proteins Melan-A and HMB45, as well as retaining SMARCB1 staining. Moreover, EMPNST does not contain melanin pigment. SMARCB1-deficient tumors such as proximal type ES and myoepithelial carcinoma can also resemble EMPNST. Strong diffuse S100 staining would exclude the former, and lack of cytokeratin and/or EMA staining would be helpful in excluding the latter.
SMARCB1 loss is not a feature of sporadic solitary schwannomas. 69 However, germline SMARCB1 alterations are present in almost half of the patients with familial schwannomatosis, a neurofibromatosis syndrome of multiple schwannomas arising in patients lacking evidence of classical neurofibromatosis 2. By definition, patients with schwannomatosis lack vestibular and intradermal schwannomas. 70 These syndromic schwannomas arise in peripheral nerves and spinal nerve roots and are often painful. 32 The genetics of this rare condition are complex. In some, but not all patients with schwannomatosis, there appears to be a 4-hit tumorigenic model in which a germline SMARCB1 inactivating mutation is followed by a 22q loss or deletion that encompasses both NF2 and the second SMARCB1 locus, and finally by a mutation of the second NF2 locus. 71 Other patients with familial schwannomatosis carry underlying LZTR1 mutations. 72, 73 Unlike the tumors present in RTPS, the neoplasms of schwannomatosis tend to have a mosaic pattern of SMARCB1 expression. 18 Interestingly, this mosaic pattern of SMARCB1 expression is also seen in NF2-associated schwannomas and other forms of schwannomatosis regardless of the underlying gene mutation, but not in sporadic solitary schwannomas which likely have a different pattern of tumorigenesis. 74 
Chordoma
Chordomas are malignant neoplasms of the skull base and spine thought to arise from notochordal remnants. Primarily occurring as slow-growing tumors in adults, they often arise from the cervical and spheno-occipital regions in children. 75 Pediatric chordomas often behave aggressively and may have atypical histologic features, including increased mitotic activity, greater cytologic atypia, and increased cellularity. Although typical chordomas demonstrate retention of SMARCB1, poorly differentiated variants have shown loss of SMARCB1. 76 As poorly differentiated chordomas consistently express nuclear brachyury, a fairly specific marker for notochordal derivation, and AT/RTs only rarely express it (7% frequency), it is unlikely that poorly differentiated chordomas with SMARCB1 loss are truly AT/RTs. 77 In contrast to AT/RT, loss of SMARCB1 expression in chordoma is more commonly due to deletions than point mutations. 77 Microscopically, poorly differentiated chordomas are disposed into patternless sheets or poorly formed nodules of medium to large epithelioid cells which may have variable rhabdoid features (Figure 16 ). Cytoplasmic vacuolization may be present but is often inconspicuous, and necrosis and mitotic activity is common. Nuclei may be pleomorphic and nucleoli are prominent. As contrasted with typical chordoma, there is less of a physalipherous pattern with increased cellularity and decreased myxoid background. In addition to brachyury, poorly differentiated chordomas express wide spectrum cytokeratins, EMA, S100, and vimentin. Most show nuclear SMARCB1 loss. 77 Brachyury positivity is therefore a key element in distinguishing poorly differentiated chordoma from MRT or AT/RT and other SMARCB1-deficient mimics.
Myoepithelial Carcinoma
In adults, myoepithelial tumors commonly occur in salivary glands and are usually benign, with salivary gland pleomorphic adenoma representing the best known myoepithelial tumor in general pathology practice. In contrast, pediatric myoepithelial tumors are rare, often arise in soft tissue of the extremities and trunk, and may be aggressive, with a 65% rate of malignancy documented in one series. 78 Metastastic sites have included lung, lymph nodes, soft tissue, brain, skin, and bone. Malignant myoepithelial tumors are referred to as myoepithelial carcinomas, and a subset of these malignancies demonstrate immunohistochemical loss of SMARCB1 protein. Interestingly, loss of SMARCB1 expression is significantly more frequent in pediatric cases (40%) than in adult cases (10%), hence their inclusion in this review. 79 There is a considerable histologic and immunohistochemical overlap between myoepithelial carcinoma and MRT, and it is possible that the poor prognosis attributed to this tumor may be partly due to inclusions of MRT and other SMARCB1-deficient tumors in some of the earlier series. SMARCB1 loss does not appear to be a feature of benign myoepitheliomas. 80 Given their rarity, heterogenous histologic appearance, and variable immunohistochemical staining patterns, pediatric myoepithelial carcinomas can be a significant diagnostic challenge. Most are characterized by mixed growth patterns and variable cytologic features ( Figure 17) . Tumors often have a multinodular architectural pattern, and most consistently present are epithelioid cells with moderate to severe nuclear atypia, vesicular nuclei, prominent nucleoli, and abundant eosinophilic cytoplasm. 79 Other myoepithelial cell types (plasmacytoid, clear cell, and spindle cell) are commonly present as well. Mitotic figures may be frequent. Necrosis is seldom seen in benign myoepitheliomas but is often present in myoepithelial carcinomas. Tumor cells may be disposed in trabeculae, solid sheets and nests, and tumor cells may also be spindled or round. Vacuolated cells can be present, and in older literature prior to the elucidation of myoepithelioma, tumors with this predominant feature were referred to as parachordomas. 78 Myoepithelial carcinomas commonly harbor a myxoid to hyalinized background, and heterologous mesenchymal elements such as cartilage, bone, and fat may be present, as well as foci of ductal differentiation. 80 Frankly sarcomatous areas are rare.
The immunohistochemical hallmark of myoepithelial carcinomas is coexpression of epithelial markers and S100. Over 90% will express a broad spectrum cytokeratin (CAM5.2 or AE1/AE3), whereas EMA expression is less common, with considerable variation in frequency in reported series, ranging from 19% to 66%. 78 Approximately half will express GFAP, and the expression of myogenic markers can also be quite variable. Most will stain with calponin, albeit weakly, and the literature reports widely variable results with CD10, smooth muscle actin, and muscle specific actin. The great majority of cases tested have lacked desmin staining. 78 Diffuse membranous CD99 staining is not seen. As mentioned earlier, loss of SMARCB1 is frequently present in childhood cases.
Approximately 45% of myoepithelial tumors of soft tissue and bone have fusions involving EWSR1.
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Fusion partners include ZNF444, PBX1, KLF17, POU5F1, and PBX3. 58 Rarely, FUS can substitute as a translocation partner for EWSR1. POU5F1 translocations may correlate with a pattern of nested epithelioid cells with clear cytoplasm, whereas PBX1 translocations may have an association with spindle cells enmeshed in a sclerotic background. 81 In a recent study of EWSR1 translocation negative myoepithelial carcinomas with loss of SMARCB1 expression, three-fifths demonstrated homozygous SMARCB1 deletions, suggesting that SMARCB1 gene abnormalities may be an alternative tumorigenic mechanism to EWSR1 translocations in these tumors. 19 All 3 of these tumors had focal areas of rhabdoid cytomorphology.
Myoepithelial carcinoma should also be distinguished from extraskeletal myxoid chondrosarcoma (EMCS), as both entities share similar histologic features, both can harbor EWSR1 gene translocations, and the immunohistochemical profile of epithelial marker and S100 positivity may overlap. 81 Although mainly a tumor of adults, EMCS has been described in children. 82, 83 Usually, the question of how to differentiate the two can be resolved by molecular means, as unlike myoepithelial carcinoma, almost all cases of EMCS have an NR4A3 gene rearrangement which can be interrogated by FISH.
84
NR4A3 in most cases is fused with EWSR1. Other fusion partners of NR4A3 described in EMCS include TAF15, TCF12, and TFG.
84 Although 4 cases of ECMS in one study had loss of reactivity for SMARCB1, it is not clear yet whether ECMS should be placed on the list of SMARCB1-deficient tumors, as those 4 cases lacked rearrangement of NR4A3. 85 In a more recent EMCS study, SMARCB1 was immunohistochemically retained in 5 cases with rhabdoid morphologic features, further raising doubt that ECMS with rhabdoid features are truly SMARCB1-deficient tumors. 84 
Sinonasal Carcinoma
Recently, a small number of sinonasal carcinomas with loss of SMARCB1 expression have been reported. 86, 87 Although predominantly seen in adults with a mean age in the 50s, 2 cases in teenagers have been described. SMARCB1-deficient sinonasal carcinomas are histologically characterized by either a mainly basaloid or a plasmacytic/rhabdoid morphology, and occasional tumors also have glandular differentiation. The basaloid tumors resemble basaloid squamous cell carcinoma, sinonasal undifferentiated carcinoma, or other ''small blue round cell'' tumors. 20 None have had squamous differentiation. In addition to SMARCB1 loss, nearly all express pancytokeratin, and all to date have been NUT, HPV, and EBV negative. They appear to be aggressive, and in the largest series reported to date, over half of patients have died of disease. 20 Tumors With Reduced SMARCB1 Expression Synovial Sarcoma
Unlike the tumors described earlier, synovial sarcoma (SS) is typified by a variable loss of SMARCB1 expression, ranging from complete retention to weak expression (most common) to near complete loss. Hoot et al. 13 first demonstrated variable SMARCB1 staining in 3 cases of synovial sarcoma, and subsequent studies have demonstrated partial to near complete loss of SMARCB1, without evidence of reduced SMARCB1 RNA. 88, 89 Several more recent studies have documented that decreased or weak to absent SMARCB1 immunohistochemical reactivity is present in 88% to 94% of synovial sarcomas, regardless of morphologic subtype; a pattern that is diagnostically useful. [90] [91] [92] Reduced SMARCB1 expression in SS is an epigenetic finding involving interaction of the fusion protein and SMARCB1. Wild-type SS18 is an integral component of the SWI/SNF chromatin remodeling complex, and the synovial sarcoma fusion protein SS18-SSX competes with wild-type SS18 for assembly of the complex, resulting in an altered structure lacking SMARCB1, hence reduced SMARCB1 expression by immunohistochemistry. 93 Interestingly, SMARCB1 expression status does not appear predictive of tumor behavior. 88 Synovial sarcomas are rare, comprising between 5% and 10% of pediatric sarcomas. Capable of occurring at any age, ranging from the newborn to the extremely aged, their incidence peaks in adolescence and early adulthood. 94 The most common locations are the deep soft tissues of the extremities, but synovial sarcomas can also arise in a wide variety of anatomic sites, including visceral organs and the head and neck. Exceptionally, these tumors may arise within bone, nerves, or intracranially. 94 The tumor tends to be slow growing, and symptoms may precede diagnosis by many years. Tumors typically are large at diagnosis, ranging from 3 to 10 cm in greatest dimension, but smaller tumors, mainly arising superficially, occur as well. SS are high-grade malignant tumors. Although older studies documented 10-year overall adult and pediatric survival rates of only 50%, 95 a more recent European prospective clinical trial study has been more encouraging, with overall survival at 5 years of 91%. 96 The most common metastatic sites are lung and pleura. High histologic grade, tumor size at presentation 5 cm, and presence of metastatic disease are associated with poorer survival. 94 In its classic histologic form, SS displays an infiltrative biphasic pattern of spindled cells and epithelial glandular components ( Figure 18 ). The slightly more common form in children is monophasic, without gland formation. Monophasic SS is composed of hypercellular, tightly packed spindle cell fascicles, often arranged in a herringbone or fibrosarcoma-like pattern. Rarely these tumors may display nuclear palisading. Tumor cells have scant cytoplasm and elongated vesicular nuclei with inconspicuous nucleoli. There is usually little background stroma, although in some cases the stroma can be collagenized or myxoid. Cystic degeneration may be present.
The biphasic form of SS consists of spindled cell fascicles (similar to the monophasic form) with the addition of variably prominent gland-like elements. These epithelial structures range from well-differentiated glands to more poorly differentiated solid epithelial areas. As compared to MPNSTs with divergent differentiation, goblet cells are not found in SS glandular epithelium. Areas of calcification can be seen in up to a third of SS and may be extensive. Less differentiated forms of SS may assume a small round cell appearance or a predominantly epithelioid appearance, creating diagnostic challenges, particularly with MPNSTs and Ewing sarcomas.
The vast majority of both monophasic and biphasic SS express broad spectrum cytokeratins such as AE1/AE3 and CAM5.2, and/or EMA, as well as vimentin and bcl-2. It is important to be aware that cytokeratin and EMA staining can be patchy and focal and may be absent in small biopsy samples. Approximately one-third express S100, many express NY-ESO-1, and more than half will express cytoplasmic CD99. TLE1 (transducer-like enhancer of split 1) has recently become an additional immunohistochemical marker. TLE1 nuclear expression is a very sensitive marker for SS, present in over 90% of cases. [97] [98] [99] However, the specificity of TLE1 for synovial sarcoma is limited, and in the study of Kosemehmetoglu et al., 37% of nonsynovial sarcoma cases stained with TLE1, including 30% of their MPNSTs and 100% of their schwannomas. Many of the SS mimics demonstrated only weak TLE1 expression as opposed to robust expression in SS with typically more than 50% of nuclei in SS strongly positive. Hence, moderate to strong TLE1 expression in greater than 50% of tumor nuclei can be very helpful in diagnosing SS.
The gold standard for SS diagnosis is molecular demonstration of its characteristic fusion. In at least 95% of SS, a t(X;18)(p11.2;q11.2) translocation is demonstrable, in which the SS18 gene (previously known as SYT) on chromosome 18 is juxtaposed with one of the SSX genes on chromosome X. 100 The majority of fusions involve SSX1 and SSX2, with rare examples of fusions involving SSX4.
101 This translocation appears specific and has not been associated with other tumor types. 102, 103 The fusion partner (SSX1 vs SSX2) correlates with the morphologic pattern, as SSX1 cases are almost always biphasic, whereas SSX2 cases are almost monophasic. 104, 105 The differential diagnosis of pediatric monophasic synovial sarcoma is mainly with other fibrosarcoma-like spindle cell neoplasms, such as MPNST, leiomyosarcoma, infantile fibrosarcoma, spindle cell rhabdomyosarcoma, and gastrointestinal stromal tumor. Of course, if an SS18-SSX fusion is demonstrated, these other entities can be confidently ruled out. MPNST can be histologically similar to SS, but clues to the diagnosis of MPNST would include origin in a nerve or preexisting neurofibroma or in a patient with neurofibromatosis 1. MPNSTs tend to be more heterogenous histologically than SS, with more atypia. Immunohistochemistry for SOX10, may also be useful, as most MPNSTs will express it as compared to fewer than 10% of SS. 106 In addition, loss of H3K27me3 expression by immunohistochemistry appears to be a specific and fairly sensitive marker for MPNST. 66 Leiomyosarcomas have shorter fascicles, nontapered blunt nuclei, and most importantly are strongly positive for smooth muscle markers, unlike SS. In addition to harboring its own characteristic fusion (ETV6-NTRK), infantile fibrosarcoma does not express cytokeratins. Moreover, although SS can occur at all ages, it is rare in infancy. Spindle cell rhabdomyosarcoma should express myogenin and MyoD1, unlike SS. Gastrointestinal stromal tumor, in both intestinal and extraintestinal anatomic sites, can be differentiated from SS by the expression of CD117 and DOG1.
The poorly differentiated form of SS can easily be confused with Ewing sarcoma, particularly since its small cell appearance is at variance with the typical expectation for SS. Clues that such a tumor may actually be a SS would include a cytoplasmic pattern of CD99 expression (as opposed to membranous), strong TLE1 nuclear expression, and expression of CK7. 107 
Tumors With Deficiency of Other SWI/SNF Complex Members
Tumors that display loss of expression of other members of the SWI-SNF complex have been described in a wide variety of mainly adult carcinomas. Of note, SMARCA4 loss has also recently been described in an aggressive subset of undifferentiated sarcoma of the lung in young adults. 108 Tumors with non-SMARCB1 SWI/SNF family member deficiency that have a significant incidence in the pediatric age-group include a subgroup of AT/RT (mentioned earlier), small cell carcinoma of the ovary of the hypercalcemic type, 109 and a subset of medulloblastomas. 110 For these tumors, SMARCA4 (BRG1) immunostaining is lost.
Rhabdoid Tumor Predisposition Syndrome
Approximately one-third of MRTs occur in patients with germline SMARCB1 mutations. 15 A much smaller number of MRT patients harbor germline SMARCA4 mutations. Most of the SMARCB1 germline mutations represent de novo events; however, these mutations can be constitutionally inherited in an autosomally dominant manner, predisposing family members to develop MRTs, a condition known as RTPS. As classified by Online Mendelian Inheritance in Man (OMIM), Type 1 RTPS (OMIM #609322) involves constitutional SMARCB1 mutations, and Type 2 RTPS (OMIM #613325) involves constitutional SMARCA4 mutations. 111 Type 1 RTPS accounts for >98% of RTPS, while Type 2 RTPS is exceedingly rare. 112 Development of MRT or other RTPS spectrum tumor would then occur following a ''second hit'' affecting the other SMARCB1/A4 allele, by either a loss of heterozygosity or a somatic mutation of the wild-type allele in the tumor. 112 In addition to MRT, carriers of germline SMARCB1 mutations have developed schwannomas, MPNSTs, CRINETs, and meningiomas. Carriers of SMARCA4 mutations have developed MRTs, ATRTs and small cell carcinomas of the ovary of the hypercalcemic type. Although loss of function mutations underlie the majority of malignant tumor formation in RTPS, missense mutations can also occur and are associated with rare developmental syndromes such as Nicolaides-Baraitser syndrome and Coffin-Siris syndrome and rarely with tumor formation. 113, 114 It has been recommended that all patients with MRT and other RTPS spectrum tumors undergo germline mutation testing in addition to somatic tumor molecular testing. 111 If germline mutations are present, the patient's parents should also undergo similar testing. A negative result would infer that the patient's germline mutation was de novo, and not inherited. However, if an inherited germline mutation is discovered, screening of other relatives should be considered, and genetic counseling and surveillance of carriers for RTPS spectrum tumors initiated. 111, 112 Given the implications for the patient and the patient's family, the role of the diagnostic pathologist should extend beyond furnishing a tissue diagnosis. Ensuring that tissue is triaged in way to optimize both morphologic diagnosis and molecular genetic testing is crucial; but beyond that, it may be the pathologist who first raises the possibility of RTPS. Somatic tumor testing can now be performed on either formalin-fixed paraffinembedded tissue or on frozen tissue, and testing for germline mutations can be performed on peripheral blood or normal tissue removed with the primary tumor.
Conclusions
Understanding of the pathology of SMARCB1-deficient tumors has increased exponentially since the first description of rhabdoid tumor of the kidney 40 years ago. With widespread adoption of a reliable SMARCB1 immunohistochemical stain, the spectrum of pediatric SMARCB1-deficient tumors has expanded beyond rhabdoid and malignant AT/RTs to include CRINET, RMC, ES, subsets of MPNSTs, schwannomas, chordomas, myoepithelial carcinomas, sinonasal carcinomas, and synovial sarcomas. These tumors have widely varying clinical behaviors, and in the great majority of cases, proper classification is possible using a multimodal approach incorporating histopathology, immunohistochemistry, and molecular diagnostics. Beyond establishing a diagnosis, the pathologist can play a crucial role in facilitating testing of the patient and patient's family for rhabdoid tumor predisposition syndrome.
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